Compositions useful for the treatment of gastrointestinal disorders
AssigneeSynergy Pharmaceuticals, Inc.
InventorKunwar Shailubhai
Life of this patent
Estimating the term…
Abstract
This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.
Claims14
A composition comprising a guanylate cyclase receptor agonist (GCRA) peptide consisting essentially of the sequence of any one of SEQ ID NOs:
- 1-54, 56-346, 371, and 372 and an anti-TNF therapy covalently linked to the N-terminus and/or the C-terminus of said peptide by a glycosidic bond, wherein when said glycosidic bond is cleaved, the peptide and the anti-TNF therapy are released to produce a colon-specific effect, and an enteric coating comprising a methacrylic acid copolymer.
A composition comprising a guanylate cyclase receptor agonist (GCRA) peptide consisting essentially of the sequence of any one of SEQ ID NOs:
- 1-54, 56-346, 371, and 372 and an anti-TNF therapy, wherein said anti-TNF therapy is covalently linked to the N terminus and/or the C terminus of said peptide by a glycosidic bond, wherein when said glycosidic bond is cleaved, the peptide and the anti-TNF therapy are released to produce a colon-specific effect.
Dependencies are inferred from the claim text.